Our findings of elevated MUFA levels and increased SCD1 activity in the liver are consistent with metabolic alterations also observed in MAFLD, which is frequently comorbid with T2D and characterized by enhanced de novo lipogenesis and hepatic triglyceride accumulation, driven in part by SCD1 upregulation [28]. The gene discussed is SCD; the disease is type 2 diabetes mellitus.